Combination therapy for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (QL1706, nab-paclitaxel, and cisplatin) as a first treatment for advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if this combination is safe and effective in shrinking tumors and helping patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell carcinoma that cannot be removed by surgery or has spread to other parts of the body.
- You have not received any prior systemic treatment for this cancer.
- You have at least one measurable tumor (a tumor that can be measured on scans).
- You are in good physical condition (able to do light activity, ECOG score 0 or 1).
- Your organ function (liver, kidneys, blood counts) is within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
This trial is testing a new immunotherapy drug (QL1706) combined with an anti-inflammatory drug (celecoxib) for advanced esophageal cancer that has progressed after previous immunotherapy. It may help slow down tumor growth and give you more treatment options.
This study tests a new treatment for people with locally advanced esophageal cancer that did not respond to initial chemotherapy and immunotherapy. The goal is to see if the study drug can shrink or control the cancer when surgery is not an option.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests a new combination of chemotherapy drugs and radiation for advanced esophageal cancer that cannot be removed with surgery. The goal is to see if this treatment can help shrink the cancer and improve outcomes.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Hear when a new QL1706 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.